Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials
about
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?Motor neuron derivation from human embryonic and induced pluripotent stem cells: experimental approaches and clinical perspectivesiPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease DevelopmentTrophic factors as modulators of motor neuron physiology and survival: implications for ALS therapyGeneration of Functional Neuromuscular Junctions from Human Pluripotent Stem Cell Lines.A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.Role of early life exposure and environment on neurodegeneration: implications on brain disordersAssisting persons with advanced amyotrophic lateral sclerosis in their leisure engagement and communication needs with a basic technology-aided program.Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative DiseasesThe role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosisBlood biomarkers for amyotrophic lateral sclerosis: myth or reality?Intricate effects of primary motor neuronopathy on contractile proteins and metabolic muscle enzymes as revealed by label-free mass spectrometry.Amyotrophic lateral sclerosis: a focus on disease progressionIncreased IL-17, a Pathogenic Link between Hepatosplenic Schistosomiasis and Amyotrophic Lateral Sclerosis: A Hypothesis.Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the futureTherapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease.Dexpramipexole is ineffective in two models of ALS related neurodegeneration.Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice.A fruitful endeavor: modeling ALS in the fruit flyModel systems of motor neuron diseases as a platform for studying pathogenic mechanisms and searching for therapeutic agents.Gene expression changes in spinal motoneurons of the SOD1(G93A) transgenic model for ALS after treatment with G-CSF.Prospects for clinical use of reprogrammed cells for autologous treatment of macular degeneration.Contra-Directional Expression of Serum Homocysteine and Uric Acid as Important Biomarkers of Multiple System Atrophy Severity: A Cross-Sectional Study.Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity.Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis surveillance in Baltimore and Philadelphia.Population-based surveillance of amyotrophic lateral sclerosis in New Jersey, 2009-2011.Age-related neurodegenerative disease research needs aging modelsExpression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanismsIntraspinal stem cell transplantation for amyotrophic lateral sclerosisCurrent Therapy of Drugs in Amyotrophic Lateral Sclerosis.Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosisGlycosylation and other PTMs alterations in neurodegenerative diseases: Current status and future role in neurotrauma.Early Cognitive/Social Deficits and Late Motor Phenotype in Conditional Wild-Type TDP-43 Transgenic Mice.Record linkage between hospital discharges and mortality registries for motor neuron disease case ascertainment for the Spanish National Rare Diseases Registry.Worming forward: amyotrophic lateral sclerosis toxicity mechanisms and genetic interactions in Caenorhabditis elegans.Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).Glia in the pathogenesis of neurodegenerative diseases.Proteome-wide analysis of neural stem cell differentiation to facilitate transition to cell replacement therapies.
P2860
Q26799233-925B7CF6-CF3E-4453-AEE6-61080D6A23D5Q26822886-B7894687-F172-488A-8E7E-0A464AC4753FQ26863612-D68B345E-1226-43D6-BE28-26A5AA69FCD1Q26999881-48E2B2DD-46B7-4CCE-833A-25F571DF159CQ27320114-C3350FC3-F783-482D-9797-46999707766DQ28082048-C8DAA817-E042-411F-93F2-767EED05E0BAQ28386323-B92F203F-554C-472A-AD72-D9E7FF931BEDQ30379572-F06E1BBD-CD99-4C55-AB65-8EE1F0107AB5Q33624586-A909453C-A07D-4DB1-80D1-A3AACB831066Q33633778-27EC9490-D175-4043-86DD-2CAEFB1E49AFQ33767845-C239FFEC-7CAD-4318-A93D-71B745C13D15Q33827791-E04BCE83-E11E-438E-A10A-7F2E03B09A79Q34064143-3C267389-8D3E-4DBD-B81D-148E961C3DD9Q34393281-32419EFA-CC4D-48CB-AD33-E49B51450FC1Q34478634-994E6B69-7D24-4F20-A0CE-020D0B77CCC7Q34557892-FF3F1A1C-3348-43AD-AE78-40DE5827411EQ34744144-1C8A361D-8F60-491B-91D5-490FCA91C998Q35137623-B1E98654-0AE4-41A4-9BE4-91462C08AC4FQ35268719-B58B3F16-918B-4D41-9EC3-EB7C2B35A44FQ35540393-384CE1FC-B22D-4A4A-86C8-20368CF6FACAQ35555633-73FA51C6-6083-4E93-9A3B-3091D3B262D5Q35608700-905DC374-6538-4D5C-8DC3-2850EB5727D7Q35820242-CB2A73F4-6B79-4E67-B8B2-60699EE1B244Q35857994-9C432ADD-BB69-4916-B2CC-1D204808864CQ35899260-6C9FCC35-DFF8-41D6-AA43-5E1E72D317E3Q35949851-B00DD43F-38E7-4AE0-948D-4038453B0841Q36003312-64B0D3E7-0F8B-4331-A174-7DD8C4DB912BQ36018230-9C41F698-264B-45C1-B89B-F9FF048ED2B7Q36601006-46345BDE-3C8A-4722-941E-8221F9B5E347Q36679757-144F2355-FA0D-448B-BF08-2D2DB5760819Q36925891-5C855931-5931-4578-AFF1-523D11998B51Q36956592-C077176C-2C91-4FB4-83DF-4DDE45F15992Q37130046-9A55ECA8-9E5A-4172-97C2-E1154643C1CCQ37516116-C1541E52-C4A8-4D3B-8881-90A430D5E07DQ38196941-2EA0E9E7-2C33-4E04-B92B-8D39AFF46141Q38214677-719030B8-875C-4B8A-81CA-C76015424012Q38223292-F65E98F9-8D47-4E95-B0BD-5E4DEE5C62FCQ38232360-9A484233-731A-410B-A917-002B53507888Q38252271-6019F838-C653-4EC7-9974-56F7DC6F4D9FQ38264328-2EB8612D-E3BF-43CE-AB27-EB8F123E0597
P2860
Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@ast
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@en
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@nl
type
label
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@ast
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@en
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@nl
prefLabel
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@ast
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@en
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@nl
P2860
P3181
P356
P1433
P1476
Amyotrophic Lateral Sclerosis: ...... agement and Therapeutic Trials
@en
P2093
Paul Gordon
P2860
P304
P3181
P356
10.14336/AD.2013.0400295
P407
P577
2013-10-01T00:00:00Z